MDS Pharma Services Establishes Central Lab Testing Facility in Singapore MONTREAL, July 28 /PRNewswire-FirstCall/ -- MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, announces the expansion of its central lab network with the development of a clinical safety- testing laboratory in Singapore. This new facility is an extension of the offerings MDS Pharma Services currently provides in Singapore, which includes central lab study coordination services, logistics and global clinical development services. "MDS Pharma Services' central lab expansion in Singapore is an important step in building our capabilities in Asia. This new facility is one more example of our continued investment in expanding MDS Pharma Services' geographic reach," said Alan Horgan, group vice president, Late Stage Development. Scott Neilson, vice president and general manager of MDS Pharma Services central lab, added, "Having a wholly owned laboratory in Singapore is fundamental to our strategy to provide consistency and control for our pharmaceutical and biotech sponsors on a global basis. Singapore is a key location that is central for the ASEAN (Association of South East Asian Nations) community. MDS Pharma Services also maintains the only College of American Pathologists (CAP) accredited central lab in China. Therefore, the addition of the Singapore location allows the company to offer unparalleled central lab services across Asia." The new facility's highlights include: - Safety testing analytical equipment identical to MDS Pharma Services' other central labs in Europe and North America; - Scientific leadership from Dr. Tain Chee Fei, Laboratory Director; - Participation in MDS Pharma Services' global external QC proficiency testing; - Frozen sample management facilities with -30 degrees C and -80 degrees C short and long-term sample storage; - Registration with the CAP and participation in requirements leading to accreditation; - Licensing by the Singapore Ministry of Health; - A scalable lab able to accommodate continued rapid growth of testing for clinical trials in South and Southeast Asia. While MDS Pharma Services' central lab has provided central lab testing from Singapore for several years, this is the company's first wholly owned laboratory testing facility in this country. The National University Hospital, which previously provided all of MDS Pharma Services' central lab testing in Singapore, will continue to provide specialty and esoteric testing for MDS Pharma Services. MDS Pharma Services offers a full spectrum of resources to meet the drug discovery and development needs of the pharmaceutical and biotechnology industries. With numerous facilities strategically located around the world, the company applies advanced scientific and technological expertise to each stage of the drug discovery and development process - early stage: lead optimization, pre-IND research, pharmaceutical and biopharmaceutical development, early clinical research (bioequivalence, phases I-IIa) and bioanalysis; and late stage: global clinical development (phases IIb-IV) and central lab. For more information, visit MDS Pharma Services' Web site at http://www.mdsps.com/. MDS Pharma Services is part of MDS Inc. (TSX: MDS; NYSE: MDZ), an international health and life sciences company. At MDS Inc., our 10,000 highly skilled people provide services, products and instruments enabling health sciences organizations to enhance the well being of people around the world. We focus on helping discover and test new drugs, assisting doctors to diagnose and treat patients and preventing the spread of disease. Find out more about MDS Inc. (TSX: MDS; NYSE: MDZ), at http://www.mdsintl.com/ or by calling 1-888-MDS-7222, 24 hours a day. DATASOURCE: MDS Pharma Services CONTACT: Kim Peacock, MDS Pharma Services, 621 Rose Street, Lincoln, Neb., Tel: (402) 476-2811, and visit our Web site at http://www.mdsps.com/

Copyright